Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Completed · Phase 2

Conditions studied: Tumor Pathway Activations Inhibited by Dovitinib

In brief

The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.

Key facts

Study ID
NCT01831726
Run by
Novartis Pharmaceuticals
People needed
80
Starts
2013-08-01
Expected to finish
2015-12-01
Last updated by the study team
2017-03-20

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.